Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

Abstract

In previously untreated patients who were ineligible for intensive chemotherapy, overall survival was longer and the incidence of remission was higher among patients who received azacitidine plus venetoclax than among those who received azacitidine alone. The incidence of febrile neutropenia was higher in the venetoclax-azacitidine group than in the control group. (Funded by AbbVie and Genentech; VIALE-A ClinicalTrials.gov number, NCT02993523.).

Keywords

Affiliated Institutions

• Cliniques Universitaires Saint-Luc BE
• University Hospital Ostrava CZ
• Université Paris Cité FR
• Aichi Cancer Center JP
• Harvard University US
• Assistance Publique – Hôpitaux de Paris FR
• University Hospital Ulm DE
• Helsinki University Hospital FI
• Institute of Hematology & Blood Diseases Hospital CN
• Seoul National University KR
• Ondokuz Mayıs University TR
• Monash University AU
• China Medical University Hospital TW
• Hadassah Medical Center IL
• University of California, Davis US
• Ospedale Policlinico San Martino IT
• The University of Texas MD Anderson Cancer Center US
• Biomedical Research Institute US
• University of Pennsylvania US
• AbbVie (United States) US
• New Generation University College ET
• Samsung Medical Center KR
• City of Hope US
• Hanusch Hospital AT
• University of Chicago US
• University of Zagreb HR
• Dana-Farber Cancer Institute US
• University of Helsinki FI
• University of Genoa IT
• McMaster University CA
• University Hospital Dubrava HR
• China Medical University TW
• Sungkyunkwan University KR
• Chinese Academy of Medical Sciences & Peking Union Medical College CN

Related Publications